Eck J, Langer M, Möckel B, Baur A, Rothe M, Zinke H, Lentzen H
BRAIN GmbH, Zwingenberg, Germany.
Eur J Biochem. 1999 Sep;264(3):775-84. doi: 10.1046/j.1432-1327.1999.00638.x.
Mistletoe lectin I (MLI) is the major active constituent of mistletoe extracts, which are widely used for adjuvant tumour therapy. The 66-kDa heterodimeric disulphide-linked glycoprotein is classified as type II ribosome-inactivating protein (RIP) due to the rRNA-cleaving enzyme activity of the A-subunit, also referred to as toxic entity. MLI and the close relative ricin both belong to the family of the two-chain plant type II RIP proteins. Isolation of the glycosylated proteins from plant material yield inhomogeneous material probably due to post-translational modifications. The aim of this study was to prepare pure and homogeneous protein as a prerequisite for structural and mechanistic studies in order to gain insight into the mode of action of this cytotoxic plant protein on tumour and immune cells. Of particular interest was to explain whether the differences in toxicity of ML and ricin are the result of variations of their enzymatic activities. By investigating the sequence homologies between the active sites of different RIPs we were able to deduce a set of primers which were suitable for specific amplification of the mistletoe lectin gene. Applying this PCR strategy the full-length 1923 nucleotide DNA sequence coding for the prepro-protein was obtained showing the existence of a single intron-free gene. In order to elucidate the molecular basis for the observed differences in cytotoxicity within the family of RIP the enzymatic A-subunit was expressed in a heterologous system. Expression of the A-chain in E. coli BL21/pT7 resulted in production of insoluble inclusion bodies constituting 20-30% of total protein. Refolding led to a pure and homogeneous protein species with an apparent molecular mass of 27 kDa and a pI value of 6.4. The ribosome-inactivating activity of the unglycosylated recombinant A-chain (IC50 20.5 pM) protein was in the same range as that of the glycosylated plant-derived ML A-chain (IC50 3.7 pM), which was very similar to that of ricin A-chain (IC50 4.9 pM). Thus, the higher cytotoxicity of ricin cannot be accountable for differences in the enzymatic activities of the type II RIP A-chains.
槲寄生凝集素I(MLI)是槲寄生提取物的主要活性成分,槲寄生提取物被广泛用于辅助肿瘤治疗。这种66千道尔顿的异二聚体二硫键连接的糖蛋白,由于其A亚基(也称为毒性实体)具有切割rRNA的酶活性,被归类为II型核糖体失活蛋白(RIP)。MLI和其近亲蓖麻毒素都属于双链植物II型RIP蛋白家族。从植物材料中分离糖基化蛋白会得到不均一的物质,这可能是由于翻译后修饰导致的。本研究的目的是制备纯的、均一的蛋白质,作为结构和机制研究的前提条件,以便深入了解这种细胞毒性植物蛋白对肿瘤细胞和免疫细胞的作用方式。特别感兴趣的是解释ML和蓖麻毒素毒性差异是否是其酶活性变化的结果。通过研究不同RIP活性位点之间的序列同源性,我们能够推导得出一组适合特异性扩增槲寄生凝集素基因的引物。应用这种PCR策略,获得了编码前体蛋白的全长1923个核苷酸的DNA序列,表明存在一个无内含子的单一基因。为了阐明RIP家族中观察到的细胞毒性差异的分子基础,在异源系统中表达了酶活性A亚基。在大肠杆菌BL21/pT7中表达A链,导致产生不溶性包涵体,占总蛋白的20 - 30%。复性后得到一种表观分子量为27千道尔顿、pI值为6.4的纯的、均一的蛋白。未糖基化的重组A链蛋白(IC50为20.5 pM)的核糖体失活活性与糖基化的植物来源的ML A链(IC50为3.7 pM)处于同一范围,这与蓖麻毒素A链(IC50为4.9 pM)非常相似。因此,蓖麻毒素较高的细胞毒性不能归因于II型RIP A链酶活性的差异。